December, 2022. Awarded an NIH contract titled "Advanced development of a vaccine candidate for Staphylococcus aureus infection and colonization". (Contract no. 75N93022C00057). Press release.
January 4th, 2022. Awarded an NIH Phase I STTR titled "Optimal adjuvant/antigen formulation toward a Staphylococcus aureus human vaccine" (1R41AI167268-01).
October 12th, 2021. IMMUNARTES CEO Vilasack Thammavongsa gave an oral presentation titled "A Protein A based Staphylococcus aureus vaccine with improved safety" at the World Vaccine Conference Europe.
April 16th, 2021. Awarded an NIH Phase I STTR titled "Development of a Vaccine for Staphylococcal Infections" (1R41AI157087-01A1).
October 18th, 2019. Awarded a grant from the Bill and Melinda Gates Foundation titled "3F6 Staph monoclonal antibody " (INV-003909). This project explored non-antibiotic (including monoclonal antibody) approaches to reducing and preventing antibiotic resistant sepsis in newborns.
July-August, 2018. IMMUNARTES was a finalist in the prestigious MassChallenge competition for startup companies.
December 6th, 2017. Awarded a translational award from The University of Chicago Innovation Fund to develop immune-therapeutics targeting Staphylococcus aureus. (polsky.uchicago.edu/2017/12/06/innovation-fund-invests-575000-in-biotech-companies/)
January 4th, 2022. Awarded an NIH Phase I STTR titled "Optimal adjuvant/antigen formulation toward a Staphylococcus aureus human vaccine" (1R41AI167268-01).
October 12th, 2021. IMMUNARTES CEO Vilasack Thammavongsa gave an oral presentation titled "A Protein A based Staphylococcus aureus vaccine with improved safety" at the World Vaccine Conference Europe.
April 16th, 2021. Awarded an NIH Phase I STTR titled "Development of a Vaccine for Staphylococcal Infections" (1R41AI157087-01A1).
October 18th, 2019. Awarded a grant from the Bill and Melinda Gates Foundation titled "3F6 Staph monoclonal antibody " (INV-003909). This project explored non-antibiotic (including monoclonal antibody) approaches to reducing and preventing antibiotic resistant sepsis in newborns.
July-August, 2018. IMMUNARTES was a finalist in the prestigious MassChallenge competition for startup companies.
December 6th, 2017. Awarded a translational award from The University of Chicago Innovation Fund to develop immune-therapeutics targeting Staphylococcus aureus. (polsky.uchicago.edu/2017/12/06/innovation-fund-invests-575000-in-biotech-companies/)